Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: An electrochemical cell comprises a first electrode having a first inner surface; a second electrode having a second inner surface, the second inner surface facing the first inner surface; a nanostructured material positioned on at least one of the first inner surface and second inner surface; and an ionic liquid positioned between the first inner surface and the second inner surface, the ionic liquid being in electrical communication with the first electrode and second electrode.

Abstract: In some aspects, the present disclosure provides gadolinium based sensors which may be used to image zinc ions in vivo. In some embodiments, the compounds show appropriate reactivity with zinc ions while maintaining high relaxivity to achieve improved background relative to other sensors.

Abstract: A laser scanning system for capturing an image of a specimen is described herein. The laser scanning system includes a light source configured to emit a light beam for illuminating the specimen, a scanning unit including a plurality of reflectors for scanning the light beam along first and second axes, and a data acquisition unit configured to control acquisition of the image. The laser scanning system can include a control circuit configured to receive a reference clock signal for the first reflector and generate a synchronization clock signal based on the reference clock signal. The laser scanning system can include a synchronization controller configured to control the scanning unit and the data acquisition unit. The synchronization controller can be configured to receive the synchronization clock signal, receive a plurality of imaging parameters, and generate a plurality of control signals based on the synchronization clock signal and the imaging parameters.

Abstract: Illustrative embodiments provide an electrostatic actuator and methods of making and operating an electrostatic actuator. The electrostatic actuator comprises a framework and a plurality of electrodes. The framework comprises walls defining a plurality of cells forming an array of cells. The plurality of electrodes comprise an electrode in each cell in the plurality of cells. A gap separates the electrode in each cell from the walls of the cell. The framework is configured to contract in response to an electrical signal applied between the framework and the plurality of electrodes.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.

Abstract: The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.

Abstract: Embodiments of the disclosure include methods and compositions directed to targeting of cells that express the long form of Bone marrow stromal cell antigen 2 (BST2) protein, including cancer cells that express the long isoform of BST2. In particular embodiments, monoclonal antibodies or functionally active fragments thereof are utilized to target cells that express the long isoform of BST2. The monoclonal antibodies or functionally active fragments thereof may be utilized by themselves or as part of other entities, such as cells or engineered antigen receptors. The disclosure includes methods of treatment, prevention, and/or diagnosis using the encompassed antibodies or functional fragments thereof.

Abstract: Disclosed herein are embodiments of a powered prosthesis. In one embodiment, the powered prosthesis may include a first joint actuator; a second joint actuator; a connector to connect the first joint actuator with the second joint actuator; and a power source connected with both the first and second joint actuator; wherein the first joint actuator and the second joint actuator are both at least backdrivable and configured such that when one of the first or second joint actuator is drawing power from the power source, the other of the first or second joint actuator may be generating power for the power source. In some embodiments, the first motor is at least a high output torque motor. In other embodiments, the second motor is at least a high output torque motor.

Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein and/or nucleic acid expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Abstract: Methods of preparing and using a metal-organic framework (MOF) are provided herein, including methods of using an MOF comprising a repeat unit of the formula [ML]n, wherein M is a divalent metal ion and L is a ligand of the formula: The MOFs provided herein may be used in the separation of two or more molecules from each other. In some embodiments, the molecules are ethylene and ethane. In some embodiments, UTSA-280 may be synthesized from calcium oxide (CaO) or calcium hydroxide (Ca(OH)2) and squaric acid (SA) through mechanochemical synthesis.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen COL6A3. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.

Abstract: In one embodiment, a system and method for determining a natural frequency of a structure involve modeling the structure, creating a synthesized excitation comprising a plurality of waves having various frequencies within a defined range of frequencies, applying the synthesized excitation to a base of the modeled structure, and generating response data indicative of a natural frequency of the modeled structure that is based upon the application of the synthesized excitation.

Abstract: Some methods of analyzing one or more brain lesions of a patient comprise, for each of the lesion(s), calculating one or more lesion characteristics from a first 3-dimensional (3D) representation of the lesion obtained from data taken at a first time and a second 3D representation of the lesion obtained from data taken at a second time that is after the first time. The characteristic(s) can include a change, form the first time to the second time, in the lesion's volume and/or surface area, the lesion's displacement from the first time to the second time, and/or the lesion's theoretical radius ratio at each of the first and second times. Some methods comprise characterizing whether the patient has multiple sclerosis and/or the progression of multiple sclerosis in the patient based at least in part on the calculation of the lesion characteristic(s) of each of the lesion(s).

Abstract: Cooling by a twist-untwist process, by a stretch-release process for twisted, coiled, or supercoiled yarns or fibers, and methods and systems thereof. High mechanocaloric cooling results from release of inserted twist or from stretch release for twisted, coiled, or supercoiled fibers, including natural rubber fibers, NiTi wires, and polyethylene fishing line. Twist utilization can increase cooling and cooling efficiencies. A cooler using twist insertion and release can be shorter and smaller in volume than a cooler that requires a large elastomeric elongation. The cooler system can be utilized in mechanochromic textiles and remotely readable tensile and torsional sensors.

Abstract: Provided herein are methods for producing an albumin drug conjugate. The albumin and dmg may be mixed ex vivo prior to administration. Further provided herein are methods of treating cancer comprising administering the albumin drug conjugate.

Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).